1. Molecular signatures of medullary thyroid carcinoma by matrix-assisted laser desorption/ionisation mass spectrometry imaging
   Andrew Smith et al, 2018, Journal of Proteomics CrossRef
2. Glucagon-like peptide 1 in health and disease
   Andreas Andersen et al, 2018, Nat Rev Endocrinol CrossRef
3. Challenges in the management of people with diabetes and cancer
   T. A. Chowdhury et al, 2019, Diabet. Med. CrossRef
4. Diagnostic significance of apical membranous and cytoplasmic dot-like CD26 expression in encapsulated follicular variant of papillary thyroid carcinoma: a useful marker for capsular invasion
   Shoji Takagi et al, 2020, Endocr J CrossRef
5. Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
   Brent A McLean et al, 2020 CrossRef
6. CD26/DPP-4: Type 2 Diabetes Drug Target with Potential Influence on Cancer Biology
   Emi Kawakita et al, 2021, Cancers CrossRef
7. The role of incretins and incretin-based drugs in autoimmune diseases
   Shabnam Radbakhsh et al, 2021, International Immunopharmacology CrossRef
8. Breast Cancer, Diabetes Mellitus and Glucagon-Like Peptide-1 Receptor Toward Exploring Their Possible Associations
   Naoko Hashimoto Takigami et al, 2021, Breast Cancer Res Treat CrossRef
9. Application of glucagon-like peptide-1 receptor antagonists in fibrotic diseases
   Fuxun Yang et al, 2022, Biomedicine & Pharmacotherapy CrossRef
10. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer
    Julien Bezin et al, 2023 CrossRef
11. Cancer related safety with SGLT2-i and GLP1-RAs: should we worry?
    M. Gallo et al, 2023, Diabetes Research and Clinical Practice CrossRef
12. Cancer biology in diabetes update: Focusing on antidiabetic drugs
    Emi Kawakita et al, 2024, J of Diabetes Invest CrossRef
13. A real‐world disproportionality analysis of semaglutide: Post‐marketing pharmacovigilance data
    Yikuan Du et al, 2024, J of Diabetes Invest CrossRef